IL182546A0 - Immunogenic compositions of staphylococcus epidermidis polypeptide antigens - Google Patents

Immunogenic compositions of staphylococcus epidermidis polypeptide antigens

Info

Publication number
IL182546A0
IL182546A0 IL182546A IL18254607A IL182546A0 IL 182546 A0 IL182546 A0 IL 182546A0 IL 182546 A IL182546 A IL 182546A IL 18254607 A IL18254607 A IL 18254607A IL 182546 A0 IL182546 A0 IL 182546A0
Authority
IL
Israel
Prior art keywords
immunogenic compositions
staphylococcus epidermidis
polypeptide antigens
epidermidis polypeptide
antigens
Prior art date
Application number
IL182546A
Other languages
English (en)
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of IL182546A0 publication Critical patent/IL182546A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL182546A 2004-10-21 2007-04-12 Immunogenic compositions of staphylococcus epidermidis polypeptide antigens IL182546A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62078804P 2004-10-21 2004-10-21
PCT/US2005/037746 WO2007001423A2 (en) 2004-10-21 2005-10-19 Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens

Publications (1)

Publication Number Publication Date
IL182546A0 true IL182546A0 (en) 2008-12-29

Family

ID=37595601

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182546A IL182546A0 (en) 2004-10-21 2007-04-12 Immunogenic compositions of staphylococcus epidermidis polypeptide antigens

Country Status (13)

Country Link
US (3) US8445000B2 (cg-RX-API-DMAC10.html)
EP (4) EP1802335A2 (cg-RX-API-DMAC10.html)
JP (2) JP2008517918A (cg-RX-API-DMAC10.html)
KR (1) KR20070068455A (cg-RX-API-DMAC10.html)
CN (1) CN101175508A (cg-RX-API-DMAC10.html)
AR (1) AR051826A1 (cg-RX-API-DMAC10.html)
AU (1) AU2005333603A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0516974A (cg-RX-API-DMAC10.html)
CA (1) CA2583121A1 (cg-RX-API-DMAC10.html)
IL (1) IL182546A0 (cg-RX-API-DMAC10.html)
TW (1) TW200619228A (cg-RX-API-DMAC10.html)
WO (1) WO2007001423A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200703274B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2468803B (en) * 2005-05-19 2011-01-19 Exocyte Ltd Screening methods for bacterial killing
EP2419129A2 (en) * 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
EP2473630B1 (en) * 2009-09-04 2017-11-08 QIAGEN GmbH Optimized probes and primers and methods of using same for the detection, screening, isolation and sequencing of vancomycin resistance genes and vancomycin resistant enterococci
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9655845B2 (en) * 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
MX377794B (es) * 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
JP7181208B2 (ja) * 2016-10-21 2022-11-30 ソクプラ、サイエンシズ、エ、ジェニ、エス．イー．シー． ワクチン構築物およびブドウ球菌感染症に対するその使用
SG11202106340XA (en) * 2019-01-30 2021-07-29 Fujifilm Electronic Materials Usa Inc Container and method of preparing the same
KR102627009B1 (ko) * 2021-12-17 2024-01-19 (주)메디톡스 피부 유해 세균에 대한 항세균 활성을 갖는 세균 균주, 및 이를 포함하는 약제학적 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
ES2198405T3 (es) 1991-11-22 2004-02-01 Nabi Biopharmaceuticals Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
DE69329642T3 (de) * 1992-03-19 2009-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
ES2249760T3 (es) * 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT783520E (pt) * 1994-09-21 2002-05-31 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO1997014800A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
US6168918B1 (en) 1996-01-31 2001-01-02 American Home Products Corp. Method of detecting foreign DNA integrated in eukaryotic chromosomes
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
EP2330192A1 (en) 1998-08-31 2011-06-08 The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
US6703492B1 (en) * 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
AU1478301A (en) * 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
WO2002098368A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
EP1412379B1 (en) 2001-08-02 2012-01-25 The University Of Sheffield Vaccine
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
AU2004226262A1 (en) * 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis

Also Published As

Publication number Publication date
JP2008517918A (ja) 2008-05-29
US8445000B2 (en) 2013-05-21
ZA200703274B (en) 2008-06-25
CN101175508A (zh) 2008-05-07
EP2340848A3 (en) 2011-09-14
US20150196629A1 (en) 2015-07-16
WO2007001423A3 (en) 2007-11-15
EP2298341A3 (en) 2011-07-13
WO2007001423A2 (en) 2007-01-04
EP1802335A2 (en) 2007-07-04
US20070292450A1 (en) 2007-12-20
BRPI0516974A (pt) 2008-09-30
AU2005333603A1 (en) 2007-01-04
EP2213298A3 (en) 2011-07-20
TW200619228A (en) 2006-06-16
US20130209501A1 (en) 2013-08-15
EP2340848A2 (en) 2011-07-06
EP2298341A2 (en) 2011-03-23
CA2583121A1 (en) 2007-01-04
KR20070068455A (ko) 2007-06-29
AR051826A1 (es) 2007-02-14
EP2213298A2 (en) 2010-08-04
JP2013121981A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
ZA200703274B (en) Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
IL181825A0 (en) Immunogenic composition
IL184045A0 (en) Compositions for wound healing
IL211133A (en) Preparations containing il-6 antibodies
IL245513A0 (en) Medical preparations containing ingenol-3-angelate
PL1734922T3 (pl) Kompozycje przeciwdrobnoustrojowe
GB0406819D0 (en) Controlled release compositions
IL186828A0 (en) Vaccine composition
GB0405545D0 (en) Antimicrobial composition
GB0405033D0 (en) Novel pharmaceutical compositions
GB0406378D0 (en) Novel pharmaceutical compositions
SI1896034T1 (sl) Mikronizirani sestavki tanaprogeta in postopki priprave le-tega
GB0409542D0 (en) Cosmetic compositions
EP1786873A4 (en) ANTIMICROBIAL CEMENT COMPOSITIONS
GB0428096D0 (en) Antiperspirant or deodorant compositions
IL179282A0 (en) Altered firbonectin-binding protein of staphylococcus aureus
GB0406380D0 (en) Novel pharmaceutical compositions
GB0408406D0 (en) Antiperspirant or deodorant compositions
GB0408288D0 (en) Antiperspirant compositions
GB0421079D0 (en) Immunogenic composition
GB2422107B (en) Cosmetic compositions
GB0427447D0 (en) Cosmetic compositions
GB0421291D0 (en) Aerosol-dispensed abrasive compositions
GB0425445D0 (en) Novel compositions
SI1604683T1 (sl) Vakcinski pripravki na gangliozidni osnovi za subkutano dajanje